Kava and Lab Work: The False Positive Nobody Warns You About

In 2022, the Journal of Analytical Toxicology published a case series from a New Zealand toxicology lab. Three people screened positive for amphetamines on a routine urine panel. Confirmation testing by GC-MS found no amphetamine and no amphetamine metabolites in any of them. What it found instead was kavain, the lead kavalactone in kava.

The team then spiked blank urine with kava extract and ran it through the same assay. It came back positive for amphetamine-type substances. The paper (Madhavaram, Patel and Kyle) was the first documented report of kavain causing a false-positive amphetamine result, and the platform involved was a CEDIA amphetamine reagent on a Beckman Coulter AU480 analyzer.

So the common line that kava is invisible to drug testing is half right and half misleading. Kava itself is not on any standard panel. Nobody is looking for kavalactones. But an immunoassay does not look for a molecule, it looks for a shape that fits an antibody, and kavain apparently fits one it was never meant to.

The bigger issue is your blood panel, not your urine screen

Most people worrying about kava and testing are thinking about employment screens. The more common real-world problem shows up at an annual physical.

A 2003 study out of Arnhem Land in Australia looked at 98 people, 62 of them kava users, drinking traditional water-extracted kava. Average intake was around 118 grams a week, with a median use history of about 12 years. More recent kava consumption tracked independently with higher GGT and higher alkaline phosphatase, both at p < 0.001.

One detail carries the whole thing. ALT and bilirubin were not elevated. The researchers reported the changes appeared reversible and started returning toward baseline after one to two weeks off kava, with no evidence of irreversible damage at those intake levels.

Now think about how that reads on a chart. GGT is the enzyme clinicians reach for first as an alcohol marker. A raised GGT with a raised ALP and clean transaminases is a pattern a busy provider may read as heavy drinking or as something biliary. If you drank kava the night before your blood draw and never mentioned it, you may end up explaining yourself in a conversation you did not expect to have.

Worth noting the same signature appeared at extreme intake. A 2003 study of heavily intoxicated kava drinkers, at doses far beyond anything recreational, again recorded elevated GGT and ALP alongside ataxia, tremor and sedation.

Kava can change what the lab reads on other drugs

This is the most underdiscussed mechanism, and it is not about kava showing up at all. It is about kava altering the numbers for drugs the lab is genuinely measuring.

A 2002 study in Drug Metabolism and Disposition tested kava extract against human liver microsomes. The inhibition was broad: CYP2C9 down 92 percent, CYP2C19 down 86 percent, CYP3A4 down 78 percent, CYP2D6 down 73 percent, CYP1A2 down 56 percent. CYP2A6, 2C8 and 2E1 were unaffected in that system. Methysticin and dihydromethysticin were the most potent individual inhibitors. Kavain itself barely moved the needle.

Then a 2005 human trial complicates it. Twelve volunteers took kava for 28 days with probe-drug phenotyping. The only significant result was roughly a 40 percent reduction in CYP2E1 activity. CYP1A2, 2D6 and 3A4/5 did not shift meaningfully in living people.

Those two findings disagree, and both are real. In a test tube kava hits a lot of enzymes hard. In a body, at ordinary supplement doses, the clean signal was CYP2E1. The honest read is that the interaction potential is credible but the magnitude in humans is not settled. If someone is on a medication whose blood level gets monitored, warfarin, an anticonvulsant, anything with a narrow window, that is a conversation for their prescriber before adding kava, not after an odd trough level appears.

Does kava trigger a benzodiazepine false positive?

The logic seems sound. Kava calms people, benzos calm people, so an assay should confuse them. The evidence does not support it.

Kavalactones are styrylpyrones. Structurally they have nothing in common with a benzodiazepine ring, and immunoassay antibodies are raised against structure. A 2016 PLOS ONE paper tested kavain directly on GABA-A receptors and found it does potentiate them, but the effect was unaffected by flumazenil, the benzodiazepine-site antagonist. Mutation work pointed toward transmembrane anesthetic-type sites instead. Kava reaches a similar destination by a different road.

Published lists of documented benzodiazepine false-positive causes run to dozens of pharmaceuticals, from sertraline to oxaprozin to efavirenz. Kava is not on them, and no case report establishing kava-benzodiazepine cross-reactivity appears in the literature. Absence of published cases is not proof of impossibility, and assays differ by manufacturer. But right now the amphetamine finding has evidence behind it and the benzodiazepine claim does not.

Breathalyzers, field sobriety and the kava bar problem

A breathalyzer measures ethanol. Kava root contains none, so the number will read zero. That part is simple.

Field sobriety testing is a different animal, because it measures coordination and eye movement rather than a chemical. The 2003 intoxication study found saccadic dysmetria, slowed saccades and reduced accuracy on visual search tasks that worsened as the task got harder, while complex cognition stayed intact. Translated: gaze tracking gets sloppy and balance suffers while thinking stays relatively clear. Those are exactly the things a roadside test is built to catch. Zero on the breath test and a failed walk-and-turn is a genuinely bad combination, and impaired driving statutes in most places cover any impairing substance, not just alcohol. Do not drive after heavy kava.

One more detail. Alcohol-extracted kava tinctures do contain ethanol, and enough of one could register. Water-extracted kava will not.

Dermopathy, and what the labs miss

Long-term heavy kava drinkers sometimes develop kanikani, dry scaly skin most visible on the shins and forearms. A 1990 Lancet report floated niacin deficiency as the cause. Later dermatology work has leaned toward describing it as an acquired ichthyosis rather than a nutritional deficit. The mechanism is still not nailed down. What is reasonably clear is that kanikani is a visible sign rather than a lab value, and it resolves when kava use stops. No routine panel flags it.

The liver scare, and which kava it was actually about

Europe pulled kava in the early 2000s, and the reputation has never fully recovered. The regulatory case files tell a messier story than the headlines did. Teschke's review of 31 reported cases found causality was assessable in 14. Of those, ethanolic and acetonic extracts accounted for nine, herbal mixtures for two, and aqueous preparations for three. Contributing factors included overdose, prolonged use and concurrent medications.

The chemistry gives a plausible explanation. Organic-solvent extraction pulls out over 95 percent of kavalactones versus roughly 3 percent for water, and it also concentrates compounds traditional preparation leaves behind, including flavokavain B. Pipermethystine, an alkaloid with documented hepatocyte toxicity in cell work, is concentrated in leaves and stem peelings rather than root. Only root and rhizome have been used in clinical trials. Water extracts also retain glutathione, which may matter. Germany's ban was reversed by a court in 2015.

None of that makes kava risk-free. Aqueous preparations still appear in the case files, and LiverTox puts clinically apparent injury at under 1 in 1,000,000 daily doses while noting underreporting. But the old scare rests heavily on solvent extracts and on plant material traditional drinkers never touched.

Practical takeaways

• Disclose kava before a blood draw. A raised GGT and ALP with normal ALT and bilirubin is a pattern worth explaining in advance.
• Consider timing. The Arnhem Land data showed enzyme levels drifting back toward baseline within one to two weeks of abstinence.
• A positive amphetamine screen is not the end. Confirmatory GC-MS or LC-MS/MS distinguishes kavain from amphetamine. Request confirmation and say you drink kava.
• Tell your prescriber if you take anything with monitored blood levels.
• Do not drive after kava, regardless of what a breathalyzer says.

Sourcing does the heavy lifting

Almost every serious question about kava traces back to what was in the cup. Root or aerial parts. Noble cultivar or tudei. Water or acetone. Those choices shape the flavokavain load, the pipermethystine risk and the interaction profile more than dose does.

That is the standard we work to at Healing Herbals: noble cultivar root only, traditional water extraction, no stems or leaves, and third-party lab testing on identity and purity for every batch. Knowing exactly what you are drinking is what makes the rest of this conversation possible.

This article is educational and is not medical advice. Kava is not intended to diagnose, treat, cure or prevent any disease. Talk to a qualified healthcare provider before using kava, especially if you take prescription medication, have a liver condition, drink alcohol regularly, or face scheduled drug testing.